Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;34(8):2265-2270.
doi: 10.1038/s41375-020-0914-x. Epub 2020 Jun 11.

Response to "COVID-19 in persons with haematological cancers"

Stefan Hatzl #  1 , Florian Eisner #  2 , Gernot Schilcher  2 , Philipp Kreuzer  3 , Maximilian Gornicec  1 , Philipp Eller  2 , Marianne Brodmann  4 , Peter Schlenke  5 , Martin Helmut Stradner  6 , Robert Krause  7 , Hildegard Greinix  1 , Eduard Schulz  8
Affiliations
Comment

Response to "COVID-19 in persons with haematological cancers"

Stefan Hatzl et al. Leukemia. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Inflammatory markers, clinical courses after SARS-CoV-2 convalescent plasma administration and time to negative nucleic acid test in patients with hematologic malignancies and COVID-19.
a Comparison of inflammatory markers in patients with and without hematologic malignancies. Box plots display serum ferritin (left), interleukin-6 (IL-6; middle), and C-reactive protein (CRP; right) in eight hematologic versus 70 non-hematologic patients on log-transformed y-axis. The maximum values were used in every subject, except in patients who received tocilizumab. Here, the maximum values before tocilizumab infusion were selected because serum ferritin and IL-6 would regularly increase, and CRP would decrease after tocilizumab administration. P-values were calculated with the Kruskal–Wallis test (see Supplementary information). b Clinical courses of patients UPN3 and UPN6 receiving SARS-CoV-2 convalescent plasma. Serum ferritin (ng/mL), CRP (mg/L), IL-6 (pg/mL) and the ratio of partial pressure of oxygen in blood (PaO2 in millimeters of mercury) and the fraction of oxygen in the inhaled air (FiO2) are depicted as a measure of inflammation and respiratory function, respectively. Tocilizumab was administered at a dose of 8 mg/kg body weight. Patients received 200 mL of ABO compatible SARS-CoV-2 convalescent plasma (CP) every other day for three times. CP was collected by standard apheresis and further pathogen-inactivated by INTERCEPT Blood System (Cerus, B.V. Europe). IV invasive mechanical ventilation, NIV non-invasive ventilation, P convalescent plasma, T tocilizumab, UPN unique patient number. c Time to SARS-CoV-2 qRT-PCR negativity in hematologic and non-hematologic patients. Analysis was performed with competing risk cumulative incidence estimators and Gray’s tests (see Supplementary information). Data cut off was May 12, 2020. The black line indicates non-hematologic patients, the red line patients with hematologic diseases.
See this image and copyright information in PMC

Comment on

  • COVID-19 in persons with haematological cancers.
    He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP. He W, et al. Leukemia. 2020 Jun;34(6):1637-1645. doi: 10.1038/s41375-020-0836-7. Epub 2020 Apr 24. Leukemia. 2020. PMID: 32332856 Free PMC article.

References

    1. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45. doi: 10.1038/s41375-020-0836-7. - DOI - PMC - PubMed
    1. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31:2810–8. doi: 10.1200/jco.2012.47.2365. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. (eds.) SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD. 2020. https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission.
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9. doi: 10.1001/jama.2020.6775. - DOI - PMC - PubMed
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. doi: 10.1056/nejmoa2002032. - DOI - PMC - PubMed